ChronoScale (CHRN) Valuation In Focus After Sharp Multi Year Rerating And Rich 32x Price To Sales Multiple
ChronoScale (CHRN) has drawn investor attention after recent price moves that differ from its longer multi year record, putting the AI compute platform provider’s current US$18.79 share level into sharper focus.
See our latest analysis for ChronoScale.
Recent trading has been choppy, with the 1 day share price return slipping 0.53% and the 7 day share price return down 1.83%. However, the 30 day and year to date share price returns of 20.68% and 139.67% point to strong momentum, while the 1 year total shareholder return of 350.6% contrasts with weaker 3 and 5 year total shareholder returns, suggesting a sharp rerating after a tougher multi year stretch.
If ChronoScale’s move has you rethinking AI infrastructure, this is a good moment to widen your search and check out 48 AI infrastructure stocks
With ChronoScale still loss making on US$84.38 million of revenue and a market value of about US$2.7b, the key question is whether today’s price underestimates its AI compute potential or already reflects an extended period of future growth.
Preferred Price to Sales Multiple of 32x: Is it justified?
ChronoScale’s current valuation rests on a rich P/S multiple, with the stock trading at 32x sales compared with a US IT industry average of 1.8x and a peer average of 2.4x.
The P/S ratio looks at how much investors are paying for each dollar of revenue, which can be useful when a company is still reporting losses. For a business like ChronoScale, focused on AI compute infrastructure and currently loss making on $84.38 million of revenue, this shifts attention away from profits and squarely onto what the market is willing to pay for its current top line.
A 32x P/S multiple suggests the market is assigning a premium price to ChronoScale’s revenue compared with both the broader IT sector and closer peers. With no fair ratio estimate available and no DCF fair value to cross check this, the market appears to be pricing in a meaningful level of future execution and scaling for the AI compute platform without a clear quantitative anchor.
Against an industry average P/S of 1.8x and a peer group at 2.4x, ChronoScale’s 32x stands out as materially higher, pointing to a valuation that is well ahead of sector benchmarks on current revenue alone.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Sales of 32x (OVERVALUED)
Other factors to keep on your radar
Valuation is only one piece of the picture, and ChronoScale’s qualitative flags add extra context to the current share price.
On profitability, the company is still loss making, with a reported net loss of $72.73 million and a return on equity that is in decline at 95.51%. Past earnings quality is also flagged as weak, and it is difficult to benchmark its recent earnings trend against the broader IT industry because of the current loss making position.
ChronoScale also scores 0 out of 6 on the internal value checks, and there is insufficient data to run a fair ratio valuation or a DCF style cash flow model. There is no clear view on expected revenue or earnings growth compared with either the US market or high growth thresholds, and no analyst consensus forecasts are available to fill that gap.
On governance, both the management team and the board look very new, with average tenures of around 0 to 0.1 years, and the board has 0% independent directors. That combination points to a structure that is still being put in place, which some investors may see as early stage, but it also means there is limited track record to assess decision making.
On the capital side, shareholders have been substantially diluted over the past year, and the company relies entirely on higher risk external borrowing for funding rather than lower risk sources such as customer deposits. For investors comparing ChronoScale with more established AI infrastructure stocks, these funding and dilution trends can be important when weighing potential upside against balance sheet and ownership considerations.
However, the ongoing net loss and recent shareholder dilution could quickly challenge the current AI compute narrative if sentiment around funding or execution shifts.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Next Steps
Given that backdrop, are you comfortable with how the story stacks up against the risks, or does it feel stretched at today’s price? Take a closer look at the 3 important warning signs.
Looking for more investment ideas?
If ChronoScale’s story has sharpened your thinking, do not stop here. Broaden your watchlist with ideas built from clear fundamentals and focused filters.
- Spot potential mispricings by scanning 46 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their strengths.
- Prioritise resilience by checking 63 resilient stocks with low risk scores where lower risk scores help you concentrate on steadier balance sheets and business profiles.
- Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before more investors start paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if ChronoScale might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com